BG505 SOSIP.GT1.1 gp140

2 trials

Sponsors

South African Medical Research Council

Conditions

HIV/AIDS

Phase 1

Active, not recruitingPACTR202502617314127

South African Medical Research CouncilHIV/AIDS

Start: 2024-12-02Target: 48Updated: 2026-06-22

Brilliant-011- A Phase 1 HIV Vaccine Trial to evaluate the Safety and Immunogenicity of BG505 GT1.1 and 426c.Mod.Core-C4b Immunogens in a prime-boost Combination with Saponin/monophosphoryl lipid A nanoparticles (SMNP) Adjuvant in HIV-negative Adults

Active, not recruitingPACTR202604518549022

South African Medical Research CouncilHIV/AIDS

Start: 2025-12-23Target: 20Updated: 2026-06-22